Cytomegalovirus Infections, Disease Exacerbation, Ulcerative Colitis
Conditions
Brief summary
Consequences of latent cytomegalovirus (CMV) infection reactivation on ulcerative colitis flare, as a flare-worsening factor or simple bystander, are debated. Theoretically, CMV-specific cell-mediate immune response will further categorize the patients into high or low risk of CMV colitis. The investigators thus evaluate the usefulness of CMV-specific ELISPOT assay in patient with ulcerative colitis flare to assess the the impact of CMV colitis on ulcerative colitis flare.
Detailed description
Moderate to severe ulcerative colitis patients admitted in Inflammatory Bowel Disease (IBD) center will be enrolled in this study. Eligible patients had active UC with a Mayo score of 6-12 points (moderate or severe disease activity). The investigators will evaluate whether CMV-specific cell-mediated immune response at admission will predict the risk of active cytomegalovirus infection (true pathogen versus bystander).
Interventions
None listed
Sponsors
Asan Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* moderate to severe UC require hospitalization * age 16 or more * agree with written informed consent
Exclusion criteria
* pregnancy * foreign * immunosuppressed patients
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| CMV infection | participants will be followed for the duration of hospital stay, an expected average of 2 weeks | CMV colitis (CMV disease involving the colon) was diagnosed by colonic tissue polymerase chain reaction (PCR) or immunohistochemistry (IHC) in accordance with current European guidelines |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Viral clearance from colonic mucosa | participants will be followed for the duration of hospital stay, an expected average of 2 weeks | Viral clearance from colonic mucosa was diagnosed as negative by immunohistochemistry (IHC) after a ganciclovir treatment |
| Breakthrough CMV infection | participants will be followed for the duration of hospital stay, an expected average of 2 weeks | Breakthrough CMV colitis was diagnosed by newly positive colonic tissue polymerase chain reaction (PCR) or immunohistochemistry (IHC) at the time of second colonic biopsy |
Countries
South Korea
Outcome results
None listed